Cheaper Than Noom Med for GLP-1: The Real Cost Math (2026) | Luma Health
Cost & Access · 2026

Cheaper Than Noom Med:
The Real Cost Math

Quick Verdict

Noom Med's bundled app subscription typically adds $50-$200+/month over a medication-only price — a straightforward cost gap once you run the numbers side by side.

Luma Health's flat semaglutide ($197/month) and tirzepatide ($297/month) don't include an app fee.

Here's the actual math on Noom Med's pricing versus a focused, flat-rate compounded provider, so you can see exactly where the cost difference comes from rather than taking it on faith.

What Noom Med Actually Totals

Noom Med's combined medication-plus-app pricing has been publicly reported in the $199-$399+/month range depending on medication, dose, and plan commitment. There's typically no way to access just the medication at a lower price without the bundled app subscription, since the two aren't sold separately within Noom Med's model.

What a Flat-Rate Alternative Totals

Luma Health's compounded semaglutide is $197/month and tirzepatide is $297/month, flat, with your medical evaluation, provider access, and shipping included — no app subscription bundled in. Annualized, that's $2,364/year for semaglutide or $3,564/year for tirzepatide, both without any additional coaching-platform fee.

Running the Actual Comparison

If Noom Med's combined price for your medication and dose lands at, say, $299/month ($3,588/year), and the equivalent compounded option is $197 or $297/month, the annual gap is real money — often $500-$1,500+ depending on which medication and tier you're comparing. That gap is specifically the price of the bundled coaching app, not a difference in the medication itself.

What You're Not Giving Up by Choosing Cheaper

The active ingredient and clinical mechanism are identical regardless of which licensed provider prescribes your semaglutide or tirzepatide. What you're not getting with a focused, lower-cost provider is Noom's specific behavioral-coaching content — which you can replace with a free or low-cost tracking app if you want that functionality without paying the bundled premium for it.

Which Fits You

The Noom Med premium may be worth it if you…
  • Specifically want and will use its structured coaching content
  • Value having medication and coaching in one integrated app
  • Aren't primarily optimizing for lowest total cost
A cheaper flat-rate option fits if you…
  • Want the lowest predictable monthly total
  • Don't need bundled behavioral coaching
  • Are fine using a separate, lower-cost tracking tool if wanted

Medical care,
without the app premium

Compounded semaglutide at $197/month or tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included.

Get Started → Or start your free health assessment

Frequently Asked Questions

Noom Med's bundled pricing has been reported at $199-$399+/month, compared to $197-$297/month for flat-rate compounded semaglutide or tirzepatide — the gap is largely the bundled app subscription cost.

No. The active ingredient is the same regardless of provider. What differs is pricing structure and whether behavioral coaching is bundled in.

In some cases, Noom's coaching app has been available as a standalone subscription apart from the medication program. Confirm current availability directly with Noom.

Depending on your current Noom Med tier, annual savings of roughly $500-$1,500+ have been reported by switching to a flat-rate compounded alternative instead.

Not if you share your current dose and treatment history with your new provider during intake, allowing them to continue your plan without unnecessary retitration.

Not necessarily — it depends on whether you'll use and value the bundled coaching. If you won't, a cheaper flat-rate option is the more efficient choice; if you will, the premium may be worth it.

References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
Medical Disclaimer: This article is for educational purposes and is not a substitute for professional medical advice. Individual results and needs vary; consult a licensed healthcare provider before starting, stopping, or changing any treatment or supplement. This article reflects information available as of July 2026. Luma Health's compounded medications are not themselves FDA-approved as finished drug products; their active ingredients are FDA-approved in commercial formulations such as Ozempic, Wegovy, Mounjaro, and Zepbound.